Luisa M Villar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6734417/publications.pdf

Version: 2024-02-01

136 papers	4,773 citations	109321 35 h-index	114465 63 g-index
140 all docs	140 docs citations	140 times ranked	5417 citing authors

#	Article	IF	Citations
1	Shortâ€chain fatty acids during pregnancy in multiple sclerosis: A prospective cohort study. European Journal of Neurology, 2022, 29, 895-900.	3.3	5
2	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	4.8	1
3	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving nonâ€cellâ€autonomous neuronal damage. Clinical and Translational Medicine, 2022, 12, e837.	4.0	4
4	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 761-769.	2.9	40
5	The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19. Journal of Clinical Immunology, 2021, 41, 315-323.	3.8	16
6	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	3.0	8
7	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells, 2021, 10, 119.	4.1	12
8	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment. Scientific Reports, 2021, 11, 9299.	3.3	6
9	IL-6â€“based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. Journal of Allergy and Clinical Immunology, 2021, 147, 1652-1661.e1.	2.9	14
10	Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral NaÃ¯ve B Cells in Patients With Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 683990.	2.6	1
11	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	4.8	13
12	Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
13	Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis. Aging Cell, 2021, 20, e13440.	6.7	4
14	Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. Autoimmunity Reviews, 2021, 20, 102893.	5.8	41
15	CSF Chitinase 3â€“Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
16	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	38
17	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology, 2021, 12, 760546.	4.8	3
18	Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. Frontiers in Immunology, 2021, 12, 798003.	4.8	3

#	Article	IF	Citations
19	Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis. Brain and Behavior, 2021, 11, e2405.	2.2	4
20	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55â€“IL6ST Gene Region in Immature Dendritic Cells. Frontiers in Immunology, 2021, 12, 816930.	4.8	6
21	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
22	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	3.0	5
23	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	2.4	9
24	Whole-Transcriptome Analysis in Peripheral Blood Mononuclear Cells from Patients with Lipid-Specific Oligoclonal IgM Band Characterization Reveals Two Circular RNAs and Two Linear RNAs as Biomarkers of Highly Active Disease. Biomedicines, 2020, 8, 540.	3.2	8
25	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1913.	4.8	5
26	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Scientific Reports, 2020, 10, 14244.	3.3	12
27	How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes, 2020, 12, 1813532.	9.8	24
28	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics, 2020, 12, 2065-2076.	2.1	12
29	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	2.5	1
30	Syncytinâ€1/HERVâ€W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. European Journal of Immunology, 2020, 50, 685-694.	2.9	35
31	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. Journal of Clinical Medicine, 2020, 9, 625.	2.4	5
32	Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis. Journal of the Neurological Sciences, 2020, 414, 116811.	0.6	7
33	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain, 2020, 143, 1414-1430.	7.6	92
34	Acetate correlates with disability and immune response in multiple sclerosis. PeerJ, 2020, 8, e10220.	2.0	23
35	Adaptive Features of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 2403.	4.8	17
36	Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgDâ^'CD27â^' Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients. Journal of Immunology, 2019, 203, 1650-1664.	0.8	42

#	Article	IF	Citations
37	Factors associated with dimethyl fumarate-induced lymphopenia. Journal of the Neurological Sciences, 2019, 398, 4-8.	0.6	29
38	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 1374.	4.8	35
39	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
40	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Annals of Clinical and Translational Neurology, 2019, 6, 355-363.	3.7	21
41	Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. European Journal of Neurology, 2019, 26, 1200-1204.	3.3	17
42	Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions. Journal of Neuroinflammation, 2019, 16, 220.	7.2	48
43	gMS-Classifier1 does not predict disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1010-1011.	3.0	0
44	Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. Clinica Chimica Acta, 2019, 488, 135-142.	1.1	3
45	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
46	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	3.6	21
47	Clinical usefulness of prognostic biomarkers in optic neuritis. European Journal of Neurology, 2018, 25, 614-618.	3.3	13
48	Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the â€˜hygiene hypothesisâ€™?. European Journal of Neurology, 2018, 25, 925-933.	3.3	26
49	Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine. British Journal of Dermatology, 2018, 179, 765-766.	1.5	0
50	Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. Multiple Sclerosis Journal, 2018, 24, 1317-1327.	3.0	49
51	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology, 2018, 265, 24-31.	3.6	11
52	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	3.0	11
53	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. Journal of Neuroinflammation, 2018, 15, 296.	7.2	7
54	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. Journal of Neuroinflammation, 2018, 15, 265.	7.2	25

#	Article	IF	Citations
55	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3â€like 1 and neurofilament light chain. European Journal of Neurology, 2018, 25, 1189-1191.	3.3	53
56	Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntingtonâ€™s Disease Patients. PLOS Currents, 2018, 10, .	1.4	3
57	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. Journal of Neuroimmunology, 2017, 303, 62-65.	2.3	16
58	Multimarker risk stratification approach at multiple sclerosis onset. Clinical Immunology, 2017, 181, 43-50.	3.2	9
59	Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. Bone Marrow Transplantation, 2017, 52, 832-838.	2.4	24
60	Gut dysbiosis and neuroimmune responses to brain infection with Theilerâ€™s murine encephalomyelitis virus. Scientific Reports, 2017, 7, 44377.	3.3	40
61	Decreased soluble IFN-Î² receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Multiple Sclerosis Journal, 2017, 23, 937-945.	3.0	12
62	Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients. Bone Marrow Transplantation, 2017, 52, 1206-1207.	2.4	1
63	Antiâ€<scp>SPAG</scp>16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. European Journal of Neurology, 2016, 23, 722-728.	3.3	11
64	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.1	85
65	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	2.9	31
66	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Molecular and Cellular Proteomics, 2016, 15, 318-328.	3.8	28
67	Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2016, 9, 31-43.	3.5	29
68	Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. Journal of the Neurological Sciences, 2016, 360, 41-44.	0.6	16
69	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 741-752.	3.0	26
70	GuÃa de laboratorio para el diagnÃ³stico y seguimiento de pacientes con gammapatÃas monoclonales. Revista Clinica Espanola, 2016, 216, 128-134.	0.6	1
71	Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Revista De Neurologia, 2016, 62, 559-69.	7.8	2
72	Spanish Immunology on the move. European Journal of Immunology, 2015, 45, 1580-1583.	2.9	2

#	Article	IF	Citations
73	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS ONE, 2015, 10, e0134414.	2.5	5
74	Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clinical and Experimental Immunology, 2015, 180, 243-249.	2.6	58
75	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
76	Lipidâ€specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
77	A functional variant that affects exon-skipping and protein expression ofSP140as genetic mechanism predisposing to multiple sclerosis. Human Molecular Genetics, 2015, 24, 5619-5627.	2.9	43
78	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	7.6	147
79	Genetic variability affects CNS IgG production in MS. Nature Reviews Neurology, 2015, 11, 313-314.	10.1	1
80	A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands. Multiple Sclerosis Journal, 2015, 21, 1104-1111.	3.0	12
81	Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. European Journal of Neurology, 2015, 22, 1169-1175.	3.3	46
82	Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clinica Chimica Acta, 2015, 438, 67-69.	1.1	19
83	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e47.	6.0	11
84	Identification of the major <scp>HHV</scp>â€6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis. European Journal of Neurology, 2014, 21, 1096-1101.	3.3	25
85	Validation of semaphorin 7A and ala-Î²-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. Journal of Neuroinflammation, 2014, 11, 181.	7.2	28
86	Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	5
87	Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2014, 175, 202-207.	2.6	5
88	Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma. British Journal of Haematology, 2014, 164, 752-755.	2.5	10
89	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain, 2014, 137, 2703-2714.	7.6	69
90	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. Journal of Immunology, 2014, 193, 2147-2156.	0.8	20

#	Article	IF	Citations
91	Immunoglobulin <scp>M</scp> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. Annals of Neurology, 2014, 76, 231-240.	5.3	51
92	Oligoclonal bandsâ€"a useful tool to avoid MS misdiagnosis. Nature Reviews Neurology, 2013, 9, 303-304.	10.1	9
93	Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. Journal of Neuroimmunology, 2013, 261, 98-107.	2.3	6
94	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1802-1809.	3.0	133
95	Comment on the article by Stauch et al. â€˜Intrathecal IgM synthesis in paediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysisâ€™. Multiple Sclerosis Journal, 2012, 18, 250-251.	3.0	3
96	High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clinica Chimica Acta, 2012, 413, 1813-1816.	1.1	54
97	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. Journal of Neurochemistry, 2012, 123, 568-577.	3.9	11
98	Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis. Archives of Neurology, 2012, 69, 191.	4.5	46
99	Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. Journal of Neuroimmunology, 2012, 247, 86-94.	2.3	45
100	Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology, 2012, 54, 5-12.	2.2	55
101	DRB1*03:01 Haplotypes: Differential Contribution to Multiple Sclerosis Risk and Specific Association with the Presence of Intrathecal IgM Bands. PLoS ONE, 2012, 7, e31018.	2.5	11
102	High frequency of co-infection by Epsteinâ€"Barr virus types 1 and 2 in patients with multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1295-1300.	3.0	25
103	Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. Journal of Immunological Methods, 2011, 371, 170-173.	1.4	25
104	Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. Multiple Sclerosis Journal, 2011, 17, 690-694.	3.0	25
105	The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. Journal of Neuroimmunology, 2010, 226, 143-146.	2.3	34
106	Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clinical Immunology, 2010, 137, 51-59.	3.2	30
107	Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Multiple Sclerosis Journal, 2010, 16, 810-815.	3.0	19
108	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain, 2010, 133, 1082-1093.	7.6	240

#	Article	IF	Citations
109	Importance of age at diagnosis in multiple sclerosis. Expert Review of Neurotherapeutics, 2010, 10, 341-342.	2.8	2
110	CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. Journal of Neuroimmunology, 2009, 211, 101-104.	2.3	33
111	Multiple sclerosis patients with antiâ€lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. European Journal of Neurology, 2009, 16, 380-385.	3.3	24
112	Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. Clinical and Experimental Immunology, 2008, 82, 390-395.	2.6	48
113	Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. Journal of the Neurological Sciences, 2008, 266, 34-37.	0.6	27
114	Current concepts in immunology. Expert Review of Clinical Immunology, 2008, 4, 559-564.	3.0	0
115	Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1208-1213.	3.0	68
116	Value of oligoclonal band study in clinically isolated syndromes and multiple sclerosis. Expert Review of Neurotherapeutics, 2008, 8, 1279-1280.	2.8	1
117	Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS. Neurology, 2006, 66, 576-578.	1.1	110
118	Early Differential Diagnosis of Multiple Sclerosis Using a New Oligoclonal Band Test. Archives of Neurology, 2005, 62, 574.	4.5	59
119	Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. Journal of Clinical Investigation, 2005, 115, 187-194.	8.2	229
120	An ultrasensitive method for the detection of oligoclonal IgG bands. Journal of Immunological Methods, 2004, 284, 141-145.	1.4	47
121	Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Annals of Neurology, 2003, 53, 222-226.	5.3	153
122	Intrathecal IgM synthesis in neurologic diseases: Relationship with disability in MS. Neurology, 2002, 58, 824-826.	1.1	85
123	Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology, 2002, 59, 555-559.	1.1	119
124	CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. British Journal of Haematology, 2002, 119, 70-78.	2.5	9
125	A sensitive and reproducible method for the detection of oligoclonal IgM bands. Journal of Immunological Methods, 2001, 258, 151-155.	1.4	61
126	Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance. Human Immunology, 1999, 60, 500-509.	2.4	15

#	Article	IF	Citations
127	Increased Soluble Serum HLA Class I Antigens in Patients with Lymphoma. Human Immunology, 1997, 58, 106-111.	2.4	24
128	Methimazole Has No Dose-Related Effect on the Serum Concentrations of Soluble Class I Major Histocompatibility Complex Antigens, Soluble Interleukin-2 Receptor, and Î²2-Microglobulin in Patients with Graves' Disease. Thyroid, 1996, 6, 29-36.	4.5	31
129	Soluble Class I Antigen Secretion by Peripheral Blood Lymphocytes in Multiple Sclerosis. European Neurology, 1993, 33, 229-231.	1.4	3
130	Intrathecal synthesis of soluble class I antigens in multiple sclerosis. Journal of Neuroimmunology, 1992, 36, 77-79.	2.3	17
131	Soluble class I histocompatibility antigens (s-HLA) and beta 2-microglobulin at delivery. Clinical and Experimental Immunology, 1991, 84, 167-9.	2.6	6
132	Intrathecal synthesis of soluble class I antigens (sHLA) in patients with HIV infection and tuberculous meningitis. Journal of the Neurological Sciences, 1990, 100, 152-154.	0.6	2
133	Soluble Class 1 antigens (sHLA) in CSF and serum of patients with HIV infection. Acta Neurologica Scandinavica, 1990, 82, 14-16.	2.1	36
134	Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1194-1196.	1.9	24
135	Detection of soluble class i molecules (non hla-a or hla-b) in serum, spleen membranes and lymphocytes in culture. European Journal of Immunology, 1989, 19, 1835-1839.	2.9	29
136	Increased beta 2-microglobulin in CSF of multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 1238-1238.	1.9	6